TECH Signal 257
Compound 10 blocks GRK2 protein aggregates that fuel Alzheimer's in mice
↗
ETH Zurich researchers found that inactive GRK2 enzyme forms aggregates in brain cells during dementia, blocking mitochondria and increasing amyloid beta, and developed Compound 10 to prevent those aggregates in mice.
This identifies a drug target distinct from directly clearing amyloid, which has been the dominant but largely disappointing approach in Alzheimer's therapeutics. If the mechanism translates to humans, intervening on GRK2 aggregation could break a self-reinforcing disease cycle rather than just managing one downstream consequence.
Written by elseif from the cluster below · every claim links back to a sourceThe three things worth knowing
Inactive GRK2 clumps in brain cells during dementia, blocking mitochondrial pores and increasing amyloid beta production in a vicious cycle.
Compound 10 prevents GRK2 aggregation, reducing amyloid buildup and helping nerve cells survive in mice.
The compound also improved heart function and slowed some aging signs in mice, but all findings remain preclinical.
THE CLUSTER